New trial results from the University of Vermont and an international team of researchers show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could reduce the risk of severe disease and death.

Investigators from across the globe came together virtually July 12-15, 2021 for the University of Vermont-hosted ninth biennial "Stem Cells, Cell Therapies, and Bioengineering in Lung Biology" conference to share the latest research in the field and set priorities for their work in the future.

Understanding what happens during important conversations between seriously ill people, their families and palliative care specialists – and how they vary by cultural, clinical, and situational contexts – is essential to guide healthcare communication improvement efforts. A new computer model developed by a team of UVM researchers offers an automated and valid tool for conducting large-scale scientific analyses of these conversations.